ArticleFrontiers in nutrition2026
Routine metabolic and nutrition-related composite indices for identifying adverse cardiovascular-kidney-metabolic phenotypes: a cross-sectional study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cardiovascular-kidney-metabolic (CKM) syndrome provides an integrated framework for capturing the overlap of adiposity, metabolic dysfunction, kidney impairment, and cardiovascular risk. Whether low-cost composite biomarkers derived entirely from routine health examinations and brief questionnaires can identify adverse CKM phenotypes in preventive-care populations remains insufficiently characterized. Methods: We conducted a single-center, hospital-based cross-sectional study of adults who underwent routine health examinations at the Health Examination Center of the Second Affiliated Hospital of Shandong First Medical University between 2024 and 2025. Participants were included in the complete-case analysis based on complete data availability. Demographic, lifestyle, anthropometric, blood pressure, complete blood count, and fasting biochemical variables were used to construct anthropometric, insulin-resistance, lipid-metabolic, inflammatory, and nutrition-related indices. The primary outcome was prevalent adverse CKM phenotype, defined as CKM stage > = 2. Multivariable logistic regression, receiver operating characteristic analysis, restricted cubic spline modeling, and internally validated machine-learning models were used to evaluate associations, discrimination, non-linearity, and model interpretability. Results: Among 1,226 participants (mean [SD] age, 47.42 [13.14] years; 631 men [51.47%]), 718 (58.56%) had adverse CKM phenotype. CKM stage 2 accounted for most adverse CKM cases (693/718, 96.52%), whereas stages 3 and 4 were uncommon (9 [0.73%] and 16 [1.31%] of the total sample, respectively). After adjustment for age, sex, smoking status, alcohol status, exercise frequency, and sleep duration, the strongest associations were observed for the atherogenic index of plasma (AIP; odds ratio [OR] per 1-SD increase, 6.70; 95% CI, 5.24-8.56; Conclusion: In this single-center cross-sectional routine health examination population, adverse CKM phenotype was common but predominantly represented stage 2 disease. AIP and TyG were similarly high-performing low-cost summary markers of prevalent CKM-related metabolic risk. These findings suggest that routine composite indices may help summarize and preliminarily stratify prevalent CKM risk in health examination settings, pending external and longitudinal validation; they should not be interpreted as evidence of readiness for clinical deployment or prediction of future events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.